new glp-1 drugs in development Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Another milestone in the evolution
Description
Diabetes medications
33 Similar findings were observed in a meta-analysis of 40 trials which concluded that GLP-1RAs were highly effective at lowering circulating glucose levels without causing hypoglycemia
Hansoh Pharma is becoming an emerging leader in metabolic diseases, and we see Mercks expertise and capabilities as key to accelerating the development of this promising asset for patients worldwide. About Hansoh Pharma Hansoh Pharma is a leading pharmaceutical company in Greater China driven by innovation
GLP-1 Vasodilatation in Humans with Coronary Artery Disease Is Not Adenosine Mediated
In a post-hoc analysis of the REWIND trial, the incidence of de novo atrial arrhythmias in patients with T2D over 5 years was similar in dulaglutide and placebo groups (5.6% and 5.3%, respectively
SureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs
